Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)
Beijing, CN
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.37% | -4.94% | -11.81% | -15.44% | -27.82% | -22.87% | -49.99% | -48.27% | -62.81% | +839.30% | +839.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-19.0% Q1'26: +30.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-487.5% Q1'26: +15.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-33.1% Q1'26: -44.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-40.8% Q1'26: -15.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-10.1% ★ Q1'26: -2.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-3.3% ★ Q1'26: -4.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.00× Q1'26: -1.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.35B
est: 2.42B (-2.6%)
|
5.75B
est: 5.04B (+14.2%)
|
11.19B
est: 11.18B (+0.0%)
|
5.51B
est: 2.71B (+103.1%)
|
2.25B
est: 2.78B (-19.3%)
|
1.82B
est: 2.06B (-11.7%)
|
1.91B
1.91B – 1.91B
-7.1% YoY
|
2.20B
2.20B – 2.20B
+14.8% YoY
|
| EBITDA |
809.21M
est: 719.99M (+12.4%)
|
2.33B
est: 1.50B (+55.5%)
|
5.40B
est: 3.33B (+62.1%)
|
1.58B
est: 510.31M (+209.5%)
|
-65.06M
est: 523.50M (-112.4%)
|
-374.52M
est: 387.24M (-196.7%)
|
359.90M
359.90M – 359.90M
-7.1% YoY
|
413.09M
413.09M – 413.09M
+14.8% YoY
|
| EBIT |
724.74M
est: 615.95M (+17.7%)
|
2.24B
est: 1.28B (+74.2%)
|
5.26B
est: 2.85B (+84.7%)
|
1.36B
est: 303.32M (+349.7%)
|
-315.37M
est: 311.16M (-201.4%)
|
-741.97M
est: 230.17M (-422.4%)
|
213.92M
213.92M – 213.92M
-7.1% YoY
|
245.54M
245.54M – 245.54M
+14.8% YoY
|
| Net Income |
677.00M
est: 754.62M (-10.3%)
|
2.02B
est: 1.89B (+6.8%)
|
4.74B
est: 4.99B (-5.2%)
|
1.25B
est: -200.35M (+722.7%)
|
106.24M
est: 570.81M (-81.4%)
|
-398.27M
est: -232.28M (-71.5%)
|
-338.15M
-338.15M – -338.15M
-45.6% YoY
|
-264.99M
-264.99M – -264.99M
+21.6% YoY
|
| SGA |
558.23M
est: 609.44M (-8.4%)
|
1.49B
est: 1.27B (+16.9%)
|
3.00B
est: 2.82B (+6.3%)
|
1.62B
est: 618.75M (+161.8%)
|
457.52M
est: 634.73M (-27.9%)
|
211.22M
est: 469.53M (-55.0%)
|
436.37M
436.37M – 436.37M
-7.1% YoY
|
500.87M
500.87M – 500.87M
+14.8% YoY
|
| EPS |
0.57
est: 0.57 (+0.3%)
|
1.64
est: 1.43 (+15.0%)
|
3.79
est: 3.76 (+0.8%)
|
0.99
est: -0.16 (+734.8%)
|
0.08
est: 0.44 (-82.0%)
|
-0.31
est: -0.18 (-71.5%)
|
-0.26
-0.26 – -0.26
-45.6% YoY
|
-0.21
-0.21 – -0.21
+21.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 0.78% | 621.6K | 0.68% |
| 2 | KraneShares MSCI All China Health Care Index ETF KURE | 0.66% | 526.7K | 0.79% |
| 3 | Amundi MSCI China Tech UCITS ETF EUR CC1.PA | 0.45% | 1.30M | 0.55% |
| 4 | Amundi MSCI China Tech UCITS ETF USD CC1U.L | 0.45% | 1.31M | 0.55% |
| 5 | HSBC MSCI China A UCITS ETF HMCT.L | 0.19% | 258.1K | 0.30% |
| 6 | Samsung KODEX China CSI300 ETF 283580.KS | 0.05% | 106.6K | 0.12% |
| 7 | iShares MSCI China A UCITS ETF CNYA.L | 0.05% | 1.59M | 0.40% |
| 8 | iShares MSCI China A UCITS ETF CNYE.MI | 0.05% | 52.5K | 0.45% |
| 9 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.05% | 65.1K | 0.35% |
| 10 | iShares MSCI China A ETF CNYA | 0.05% | 107.6K | 0.60% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gangsheng Li | Accounting Supervisor | — | — |
| Pan Huirong | Deputy General Manager | — | male |
| Tao Yu | Board Secretary | — | male |
| Yun Lu | CFO & Director | — | male |
| Zhiming Jiang | GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603392.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
